Literature DB >> 12547005

Aptamers as tools for target prioritization and lead identification.

Petra Burgstaller1, Anne Girod, Michael Blind.   

Abstract

The increasing number of potential drug target candidates has driven the development of novel technologies designed to identify functionally important targets and enhance the subsequent lead discovery process. Highly specific synthetic nucleic acid ligands--also known as aptamers--offer a new exciting route in the drug discovery process by linking target validation directly with HTS. Recently, aptamers have proven to be valuable tools for modulating the function of endogenous cellular proteins in their natural environment. A set of technologies has been developed to use these sophisticated ligands for the validation of potential drug targets in disease models. Moreover, aptamers that are specific antagonists of protein function can act as substitute interaction partners in HTS assays to facilitate the identification of small-molecule lead compounds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12547005     DOI: 10.1016/s1359-6446(02)02522-9

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  7 in total

1.  Strategies for the discovery of therapeutic aptamers.

Authors:  Xianbin Yang; Na Li; David G Gorenstein
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

2.  Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus.

Authors:  Byounghoon Hwang; Jung Sun Cho; Hyeon Ju Yeo; Jung-Hye Kim; Kyung Min Chung; Kyungsook Han; Sung Key Jang; Seong-Wook Lee
Journal:  RNA       Date:  2004-07-09       Impact factor: 4.942

3.  An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro.

Authors:  Günter Mayer; Bernhard Wulffen; Christian Huber; Jörg Brockmann; Birgit Flicke; Lars Neumann; Doris Hafenbradl; Bert M Klebl; Martin J Lohse; Cornelius Krasel; Michael Blind
Journal:  RNA       Date:  2008-01-29       Impact factor: 4.942

4.  Label free inhibitor screening of hepatitis C virus (HCV) NS5B viral protein using RNA oligonucleotide.

Authors:  Changhyun Roh; Sang Eun Kim; Sung-Kee Jo
Journal:  Sensors (Basel)       Date:  2011-06-27       Impact factor: 3.576

5.  CELL-SELEX: Novel perspectives of aptamer-based therapeutics.

Authors:  Ke-Tai Guo; Gerhard Ziemer; Angela Paul; Hans P Wendel
Journal:  Int J Mol Sci       Date:  2008-04-24       Impact factor: 6.208

Review 6.  Potential diagnostic applications of biosensors: current and future directions.

Authors:  Shiping Song; Hui Xu; Chunhai Fan
Journal:  Int J Nanomedicine       Date:  2006

7.  Co-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells.

Authors:  Robert Chan; Madaline Gilbert; Kristin M Thompson; H Nicholas Marsh; David M Epstein; P Shannon Pendergrast
Journal:  Nucleic Acids Res       Date:  2006-03-03       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.